14 PhD Positions in the EU Horizon 2020 MSCA-ITN project V.A. Cure
Vascular anomalies (VAs) are a group of rare diseases defined by blood- or lymph vessel dysfunction causing chronic pain, disabilities, and even sudden death, for which effective treatments are lacking. The V.A. Cure network aims to uncover core mechanisms of initiation and maintenance of these diseases with the final goal to stablish novel therapeutic strategies for VAs.
The network is funded in the frame of the EU MSCA-ITN programme and has 9 consortium partners:
de Duve Institute (Belgium) – Uppsala University (Sweden) – Karolinska Institute (Sweden) – Potsdam University (Germany) – Max Planck Institute for Heart and Lung Research (Germany) – Oulu University (Finland) – INSERM U136 Grenoble (France) – FinnAdvance (Finland) – AstraZeneca (Sweden)
Working at one of the partners and being part of a team of 14 Early Stage Researchers (ESRs), you will be enrolled in a PhD programme and work on one of the research projects listed below. You will receive training in the fundamentals of vascular biology and state-of-the-art biomedical research techniques, as well as in generic skills like management and communication through the network’s international training programme. You will take part in networking and outreach events of the network. For short periods (several months), you will work at other universities or companies of the network.
Benefits of joining the V.A. Cure Network
Salary and appointment terms
The successful candidates will receive an attractive salary (gross salary 3.171 – 3.983 euro depending on the country), in accordance with the MSCA regulations for Early Stage Researchers. The period of employment is 3 or 4 years depending on the institution (ITN funding for first 3 years).
ESR 1 & 2: Identification of novel genes that cause Vascular Anomalies (de Duve Institute)
ESR 4: Generation and characterization of mouse models for Venous Malformation and Lymphatic Malformation (Uppsala University)
ESR 5: iPS cells for vascular anomaly research (AstraZeneca)
ESR 6: Cellular heterogeneity in vascular malformation ‐ identification of novel targets (Karolinska Institute)
ESR 9 & 10: Zebrafish models of vascular development and disease (Potsdam University)
ESR 11: Dissecting the role of FOXO transcription factors in venous and lymphatic malformations (Max Planck Institute for Heart and Lung Research)
ESR 12: Respective roles of BMP9 and BMP10 in blood and lymphatic vascular homeostasis (INSERM U136 Grenoble)
ESR 13: BMP9/10 non-Smad signalling pathways: new targets for HHT treatment? (INSERM U136 Grenoble)
ESR 14: Vascular anomaly-On-A-Chip (FinnAdvance)